Acorda Therapeutics (ACOR) 24.27 $ACOR
THE LISTING COMMITTEE OF NASDAQ HELSINKI HAS RESOLVED TO DELIST THE SHARES OF BIOTIE THERAPIES CORP.
Globe Newswire - Thu Aug 25, 6:15AM CDT
BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE 25 August 2016, at 2.15 p.m. (EET)
BITI: 25.80 (-0.71), ACOR: 24.27 (-0.07)
After Yesterday's Rally of 2.78% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Mon Aug 22, 4:40PM CDT
Acorda Therapeutics (NASDAQ:ACOR) traded in a range yesterday that spanned from a low of $24.79 to a high of $26.12. Yesterday, the shares gained 2.8%, which took the trading range above the 3-day high of $25.29 on volume of 353,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ACOR: 24.27 (-0.07)
BIOTIE THERAPIES CORP. APPLIES FOR DELISTING OF ITS SHARES FROM NASDAQ HELSINKI
Globe Newswire - Thu Aug 18, 1:55AM CDT
Acorda Therapeutics, Inc. (Nasdaq: ACOR) ("Acorda"
owns approximately 96.8 percent of all the shares and votes in Biotie (excluding the treasury shares held by Biotie). Acorda has initiated redemption proceedings in accordance with Chapter 18 of the Finnish Companies Act in order to redeem all the remaining Biotie shares held by the minority shareholders.
BITI: 25.80 (-0.71), ACOR: 24.27 (-0.07)
Acorda Provides Financial and Pipeline Update for Second Quarter 2016
BusinessWire - Thu Jul 28, 5:00AM CDT
--Company Reiterates AMPYRA 2016 Net Sales Guidance and Provides Updates on 2016 R&D and SG&A Guidance
ACOR: 24.27 (-0.07)
Anavex's Lead Candidate Gets Orphan Drug Status Yet Again
Zacks Equity Research - Zacks Investment Research - Thu Jun 23, 5:22PM CDT
Anavex Life Sciences (AVXL) announced that ANAVEX 2-73 has been granted orphan drug status by the FDA for the treatment of infantile spasms.
AVXL: 3.05 (+0.02), ANIP: 59.86 (-1.56), RTRX: 16.10 (-0.25), ACOR: 24.27 (-0.07)
Fate's (FATE) ProTmune Gets Fast Track Status, Stock Up
Zacks Equity Research - Zacks Investment Research - Tue Jun 21, 10:46AM CDT
Fate Therapeutics (FATE) announced that the FDA has granted the Fast Track status to its immunotherapy ProTmune.
FATE: 2.38 (-0.07), ANIP: 59.86 (-1.56), RTRX: 16.10 (-0.25), ACOR: 24.27 (-0.07)
7 Biotech Stocks that are Buys Right Now
Zacks Equity Research - Zacks Investment Research - Fri Jun 17, 10:00AM CDT
Buy these seven biotech stocks now and see how well the second half of 2016 unfolds for this industry.
MSTX: 0.55 (+0.03), RTRX: 16.10 (-0.25), AVEO: 0.90 (-0.01), SNSS: 0.81 (+0.01), LGND: 106.19 (-0.85), BIND: 0.78 (-0.09), ACOR: 24.27 (-0.07)
Biotie Therapies Corp. Announces That the Delisting of Its American Depositary Shares from NASDAQ Global Select Market Has Become Effective
BusinessWire - Mon Jun 13, 8:30AM CDT
Biotie Therapies Corp. (Nasdaq Helsinki: BTH1V) ("Biotie" or the "Company" announces that the voluntary delisting of its American Depositary Shares ("ADSs" from the NASDAQ Global Select Market ("Nasdaq US" became effective prior to the opening of trading on 13 June, 2016, following the filing, on 2 June 2016, of an application on Form 25 with the U.S. Securities and Exchange Commission (the "SEC" for notifying the SEC of the delisting of the Company's ADSs from NASDAQ US, as announced on 18 May 2016.
BITI: 25.80 (-0.71), ACOR: 24.27 (-0.07)
The Zacks Analyst Blog Highlights: Biogen, Merrimack Pharmaceuticals, Retrophin, Idera Pharmaceuticals and Acorda Therapeutics
Zacks Equity Research - Zacks Investment Research - Thu Jun 09, 8:30AM CDT
The Zacks Analyst Blog Highlights: Biogen, Merrimack Pharmaceuticals, Retrophin, Idera Pharmaceuticals and Acorda Therapeutics
MACK: 4.53 (-0.06), BIIB: 313.59 (+7.56), IDRA: 1.92 (unch), RTRX: 16.10 (-0.25), ACOR: 24.27 (-0.07)
Pre-market Insights on Biotechnology Stocks -- BioMarin Pharma, Alexion Pharma, Aegerion Pharma, and Acorda Therapeutics
PR Newswire - Thu Jun 09, 7:40AM CDT
On Wednesday, June 08, 2016, the NASDAQ Composite ended the trading session at 4,974.64, up 0.26%; the Dow Jones Industrial Average advanced 0.37% to finish at 18,005.05; and the S&P 500 closed at 2,119.12, up 0.33%. The gains were broad based as all the sectors ended the session in positive. ActiveWallSt.com has initiated coverage on the following equities: BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), Alexion Pharmaceuticals Inc. (NASDAQ: ALXN), Aegerion Pharmaceuticals Inc. (NASDAQ: AEGR), and Acorda Therapeutics Inc. (NASDAQ: ACOR). Learn more about these stocks by accessing their free trade alerts at:
BMRN: 95.73 (+0.54), ALXN: 123.67 (-1.96), AEGR: 1.60 (+0.01), ACOR: 24.27 (-0.07)
Acorda Presents Phase 1 Data on CVT-427 for Acute Treatment of Migraine at 58th Annual Scientific Meeting of the American Headache Society
BusinessWire - Thu Jun 09, 6:00AM CDT
Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced pharmacokinetic (PK) data from a Phase 1 study of CVT-427, an inhaled formulation of zolmitriptan, resulting in increased bioavailability and faster absorption compared to oral and nasal administration of the same active ingredient in healthy adults. The data on CVT-427, an investigational agent under development for the acute treatment of migraines, will be presented on June 10th, 2016, at the 58th Annual Scientific Meeting of the American Headache Society, in San Diego, CA.
ACOR: 24.27 (-0.07)
Forget Biogen (BIIB), Buy These 5 Biotech Stocks Instead
Arpita Dutt - Zacks Investment Research - Wed Jun 08, 9:52AM CDT
Lack of near-term pipeline catalysts, the MS franchise's performance, Tecfidera patent challenges and pipeline setbacks are some of the factors that are currently impacting Biogen (BIIB).
MACK: 4.53 (-0.06), BIIB: 313.59 (+7.56), IDRA: 1.92 (unch), RTRX: 16.10 (-0.25), LGND: 106.19 (-0.85), ACOR: 24.27 (-0.07)
Celldex (CLDX) Presents Phase II Melanoma Study Data
Zacks Equity Research - Zacks Investment Research - Mon Jun 06, 9:45AM CDT
Celldex Therapeutics (CLDX) announced positive phase II data evaluating CDX-301 and CDX-1401 in patients with malignant melanoma at ASCO.
ANIP: 59.86 (-1.56), CLDX: 3.35 (-0.01), RTRX: 16.10 (-0.25), ACOR: 24.27 (-0.07)
Acorda Therapeutics to Present at the 37th Annual Goldman Sachs Global Healthcare Conference
BusinessWire - Tue May 31, 6:00AM CDT
Acorda Therapeutics, Inc. (Nasdaq:ACOR) announced that Michael Rogers, Chief Financial Officer, will present at the Goldman Sachs Global Healthcare Conference on Tuesday, June 7 at 2:00pm PT (5:00pm ET).
ACOR: 24.27 (-0.07)
The Medicines Co. Carbavance TANGO 1 Study Enrolled
Zacks Equity Research - Zacks Investment Research - Fri May 27, 1:45PM CDT
The Medicines Company (MDCO) announced that it has completed enrollment in the phase III TANGO 1 study on Carbavance for the treatment of cUTI.
MDCO: 38.31 (-0.66), ANIP: 59.86 (-1.56), RTRX: 16.10 (-0.25), ACOR: 24.27 (-0.07)
Alkermes Begins Phase I Study on Immuno-Oncology Drug
Zacks Equity Research - Zacks Investment Research - Thu May 26, 10:30AM CDT
Alkermes (ALKS) announced the initiation of a phase I study on its immuno-oncology candidate ALKS 4230 for the treatment of solid tumors
ANIP: 59.86 (-1.56), RTRX: 16.10 (-0.25), ACOR: 24.27 (-0.07), ALKS: 45.12 (+0.38)
Biotech Stock Roundup: XenoPort Soars on Acquisition Deal, AbbVie Crohn's Disease Drug Fares Well
Arpita Dutt - Zacks Investment Research - Wed May 25, 2:02PM CDT
Deals and acquisitions were in focus this week in the biotech sector while AbbVie's (ABBV) recently in-licensed candidate fared well in a mid-stage study.
VRTX: 95.11 (+0.36), HZNP: 17.84 (-0.78), ICPT: 150.74 (+3.92), ABBV: 64.12 (+0.09), ACOR: 24.27 (-0.07), BIOD: 0.42 (unch), XNPT: 7.07 (+0.05)
Acorda Shelves Development of Epilepsy Treatment, Plumiaz
Arpita Dutt - Zacks Investment Research - Mon May 23, 6:39AM CDT
Acorda's (ACOR) decision to terminate the development of Plumiaz was based on data from ongoing studies.
HSKA: 52.49 (-0.27), ANIP: 59.86 (-1.56), RTRX: 16.10 (-0.25), ACOR: 24.27 (-0.07)
Acorda to Discontinue Development of PLUMIAZ for Treatment of Epilepsy Seizure Clusters
BusinessWire - Fri May 20, 5:00AM CDT
Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it will discontinue development of PLUMIAZ(TM) (diazepam) Nasal Spray, an investigational therapy being studied for the treatment of seizure clusters in people with epilepsy. Data from the ongoing clinical trials do not demonstrate its bioequivalence to Diastat(R) rectal gel, needed to re-file the New Drug Application (NDA) under section 505(b)(2). Specifically, the data demonstrated unexpectedly lower nasal mucosa absorption of diazepam in persons with epilepsy compared to studies in healthy volunteers.
ACOR: 24.27 (-0.07)
Biotie Therapies Corp. to Delist Its American Depositary Shares from the Nasdaq Global Select Market
BusinessWire - Wed May 18, 8:00AM CDT
Biotie Therapies Corp. ("Biotie" today announces that its Board of Directors has resolved to voluntarily delist its American Depositary Shares ("ADSs", each representing 80 Biotie ordinary shares with no nominal value ("Shares", from the NASDAQ Global Select Market ("NASDAQ US".
ACOR: 24.27 (-0.07)
THE LISTING COMMITTEE OF NASDAQ HELSINKI HAS RESOLVED TO DELIST THE SHARES OF BIOTIE THERAPIES CORP.
Globe Newswire - Thu Aug 25, 6:15AM CDT
BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE 25 August 2016, at 2.15 p.m. (EET)
BITI: 25.80 (-0.71), ACOR: 24.27 (-0.07)
After Yesterday's Rally of 2.78% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Mon Aug 22, 4:40PM CDT
Acorda Therapeutics (NASDAQ:ACOR) traded in a range yesterday that spanned from a low of $24.79 to a high of $26.12. Yesterday, the shares gained 2.8%, which took the trading range above the 3-day high of $25.29 on volume of 353,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ACOR: 24.27 (-0.07)
BIOTIE THERAPIES CORP. APPLIES FOR DELISTING OF ITS SHARES FROM NASDAQ HELSINKI
Globe Newswire - Thu Aug 18, 1:55AM CDT
Acorda Therapeutics, Inc. (Nasdaq: ACOR) ("Acorda"
owns approximately 96.8 percent of all the shares and votes in Biotie (excluding the treasury shares held by Biotie). Acorda has initiated redemption proceedings in accordance with Chapter 18 of the Finnish Companies Act in order to redeem all the remaining Biotie shares held by the minority shareholders. BITI: 25.80 (-0.71), ACOR: 24.27 (-0.07)
Acorda Provides Financial and Pipeline Update for Second Quarter 2016
BusinessWire - Thu Jul 28, 5:00AM CDT
--Company Reiterates AMPYRA 2016 Net Sales Guidance and Provides Updates on 2016 R&D and SG&A Guidance
ACOR: 24.27 (-0.07)
Anavex's Lead Candidate Gets Orphan Drug Status Yet Again
Zacks Equity Research - Zacks Investment Research - Thu Jun 23, 5:22PM CDT
Anavex Life Sciences (AVXL) announced that ANAVEX 2-73 has been granted orphan drug status by the FDA for the treatment of infantile spasms.
AVXL: 3.05 (+0.02), ANIP: 59.86 (-1.56), RTRX: 16.10 (-0.25), ACOR: 24.27 (-0.07)
Fate's (FATE) ProTmune Gets Fast Track Status, Stock Up
Zacks Equity Research - Zacks Investment Research - Tue Jun 21, 10:46AM CDT
Fate Therapeutics (FATE) announced that the FDA has granted the Fast Track status to its immunotherapy ProTmune.
FATE: 2.38 (-0.07), ANIP: 59.86 (-1.56), RTRX: 16.10 (-0.25), ACOR: 24.27 (-0.07)
7 Biotech Stocks that are Buys Right Now
Zacks Equity Research - Zacks Investment Research - Fri Jun 17, 10:00AM CDT
Buy these seven biotech stocks now and see how well the second half of 2016 unfolds for this industry.
MSTX: 0.55 (+0.03), RTRX: 16.10 (-0.25), AVEO: 0.90 (-0.01), SNSS: 0.81 (+0.01), LGND: 106.19 (-0.85), BIND: 0.78 (-0.09), ACOR: 24.27 (-0.07)
Biotie Therapies Corp. Announces That the Delisting of Its American Depositary Shares from NASDAQ Global Select Market Has Become Effective
BusinessWire - Mon Jun 13, 8:30AM CDT
Biotie Therapies Corp. (Nasdaq Helsinki: BTH1V) ("Biotie" or the "Company"
announces that the voluntary delisting of its American Depositary Shares ("ADSs" from the NASDAQ Global Select Market ("Nasdaq US" became effective prior to the opening of trading on 13 June, 2016, following the filing, on 2 June 2016, of an application on Form 25 with the U.S. Securities and Exchange Commission (the "SEC" for notifying the SEC of the delisting of the Company's ADSs from NASDAQ US, as announced on 18 May 2016. BITI: 25.80 (-0.71), ACOR: 24.27 (-0.07)
The Zacks Analyst Blog Highlights: Biogen, Merrimack Pharmaceuticals, Retrophin, Idera Pharmaceuticals and Acorda Therapeutics
Zacks Equity Research - Zacks Investment Research - Thu Jun 09, 8:30AM CDT
The Zacks Analyst Blog Highlights: Biogen, Merrimack Pharmaceuticals, Retrophin, Idera Pharmaceuticals and Acorda Therapeutics
MACK: 4.53 (-0.06), BIIB: 313.59 (+7.56), IDRA: 1.92 (unch), RTRX: 16.10 (-0.25), ACOR: 24.27 (-0.07)
Pre-market Insights on Biotechnology Stocks -- BioMarin Pharma, Alexion Pharma, Aegerion Pharma, and Acorda Therapeutics
PR Newswire - Thu Jun 09, 7:40AM CDT
On Wednesday, June 08, 2016, the NASDAQ Composite ended the trading session at 4,974.64, up 0.26%; the Dow Jones Industrial Average advanced 0.37% to finish at 18,005.05; and the S&P 500 closed at 2,119.12, up 0.33%. The gains were broad based as all the sectors ended the session in positive. ActiveWallSt.com has initiated coverage on the following equities: BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), Alexion Pharmaceuticals Inc. (NASDAQ: ALXN), Aegerion Pharmaceuticals Inc. (NASDAQ: AEGR), and Acorda Therapeutics Inc. (NASDAQ: ACOR). Learn more about these stocks by accessing their free trade alerts at:
BMRN: 95.73 (+0.54), ALXN: 123.67 (-1.96), AEGR: 1.60 (+0.01), ACOR: 24.27 (-0.07)
Acorda Presents Phase 1 Data on CVT-427 for Acute Treatment of Migraine at 58th Annual Scientific Meeting of the American Headache Society
BusinessWire - Thu Jun 09, 6:00AM CDT
Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced pharmacokinetic (PK) data from a Phase 1 study of CVT-427, an inhaled formulation of zolmitriptan, resulting in increased bioavailability and faster absorption compared to oral and nasal administration of the same active ingredient in healthy adults. The data on CVT-427, an investigational agent under development for the acute treatment of migraines, will be presented on June 10th, 2016, at the 58th Annual Scientific Meeting of the American Headache Society, in San Diego, CA.
ACOR: 24.27 (-0.07)
Forget Biogen (BIIB), Buy These 5 Biotech Stocks Instead
Arpita Dutt - Zacks Investment Research - Wed Jun 08, 9:52AM CDT
Lack of near-term pipeline catalysts, the MS franchise's performance, Tecfidera patent challenges and pipeline setbacks are some of the factors that are currently impacting Biogen (BIIB).
MACK: 4.53 (-0.06), BIIB: 313.59 (+7.56), IDRA: 1.92 (unch), RTRX: 16.10 (-0.25), LGND: 106.19 (-0.85), ACOR: 24.27 (-0.07)
Celldex (CLDX) Presents Phase II Melanoma Study Data
Zacks Equity Research - Zacks Investment Research - Mon Jun 06, 9:45AM CDT
Celldex Therapeutics (CLDX) announced positive phase II data evaluating CDX-301 and CDX-1401 in patients with malignant melanoma at ASCO.
ANIP: 59.86 (-1.56), CLDX: 3.35 (-0.01), RTRX: 16.10 (-0.25), ACOR: 24.27 (-0.07)
Acorda Therapeutics to Present at the 37th Annual Goldman Sachs Global Healthcare Conference
BusinessWire - Tue May 31, 6:00AM CDT
Acorda Therapeutics, Inc. (Nasdaq:ACOR) announced that Michael Rogers, Chief Financial Officer, will present at the Goldman Sachs Global Healthcare Conference on Tuesday, June 7 at 2:00pm PT (5:00pm ET).
ACOR: 24.27 (-0.07)
The Medicines Co. Carbavance TANGO 1 Study Enrolled
Zacks Equity Research - Zacks Investment Research - Fri May 27, 1:45PM CDT
The Medicines Company (MDCO) announced that it has completed enrollment in the phase III TANGO 1 study on Carbavance for the treatment of cUTI.
MDCO: 38.31 (-0.66), ANIP: 59.86 (-1.56), RTRX: 16.10 (-0.25), ACOR: 24.27 (-0.07)
Alkermes Begins Phase I Study on Immuno-Oncology Drug
Zacks Equity Research - Zacks Investment Research - Thu May 26, 10:30AM CDT
Alkermes (ALKS) announced the initiation of a phase I study on its immuno-oncology candidate ALKS 4230 for the treatment of solid tumors
ANIP: 59.86 (-1.56), RTRX: 16.10 (-0.25), ACOR: 24.27 (-0.07), ALKS: 45.12 (+0.38)
Biotech Stock Roundup: XenoPort Soars on Acquisition Deal, AbbVie Crohn's Disease Drug Fares Well
Arpita Dutt - Zacks Investment Research - Wed May 25, 2:02PM CDT
Deals and acquisitions were in focus this week in the biotech sector while AbbVie's (ABBV) recently in-licensed candidate fared well in a mid-stage study.
VRTX: 95.11 (+0.36), HZNP: 17.84 (-0.78), ICPT: 150.74 (+3.92), ABBV: 64.12 (+0.09), ACOR: 24.27 (-0.07), BIOD: 0.42 (unch), XNPT: 7.07 (+0.05)
Acorda Shelves Development of Epilepsy Treatment, Plumiaz
Arpita Dutt - Zacks Investment Research - Mon May 23, 6:39AM CDT
Acorda's (ACOR) decision to terminate the development of Plumiaz was based on data from ongoing studies.
HSKA: 52.49 (-0.27), ANIP: 59.86 (-1.56), RTRX: 16.10 (-0.25), ACOR: 24.27 (-0.07)
Acorda to Discontinue Development of PLUMIAZ for Treatment of Epilepsy Seizure Clusters
BusinessWire - Fri May 20, 5:00AM CDT
Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it will discontinue development of PLUMIAZ(TM) (diazepam) Nasal Spray, an investigational therapy being studied for the treatment of seizure clusters in people with epilepsy. Data from the ongoing clinical trials do not demonstrate its bioequivalence to Diastat(R) rectal gel, needed to re-file the New Drug Application (NDA) under section 505(b)(2). Specifically, the data demonstrated unexpectedly lower nasal mucosa absorption of diazepam in persons with epilepsy compared to studies in healthy volunteers.
ACOR: 24.27 (-0.07)
Biotie Therapies Corp. to Delist Its American Depositary Shares from the Nasdaq Global Select Market
BusinessWire - Wed May 18, 8:00AM CDT
Biotie Therapies Corp. ("Biotie"
today announces that its Board of Directors has resolved to voluntarily delist its American Depositary Shares ("ADSs", each representing 80 Biotie ordinary shares with no nominal value ("Shares", from the NASDAQ Global Select Market ("NASDAQ US". ACOR: 24.27 (-0.07)
